A carregar...
Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor
Imatinib, a selective KIT tyrosine-kinase inhibitor is considered standard first line therapy in metastatic gastrointestinal stromal tumors (GISTs). However, up to 40-50% of patients develop resistance to imatinib resulting in progression of disease. Other kinase inhibitors such as sunitinib, and mo...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3904027/ https://ncbi.nlm.nih.gov/pubmed/24490049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2013.058 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|